Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation:: high rates of reactivation in patients with multiple myeloma and lymphoma

被引:42
作者
Fassas, ABT [1 ]
Bolaños-Meade, J [1 ]
Buddharaju, LN [1 ]
Rapoport, A [1 ]
Cottler-Fox, M [1 ]
Chen, T [1 ]
Lovchik, JC [1 ]
Cross, A [1 ]
Tricot, G [1 ]
机构
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
关键词
cytomegalovirus; autologous stem cell transplantation; non-neutropenic fever; multiple myeloma; lymphoma;
D O I
10.1046/j.1365-2141.2001.02487.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In a retrospective study, we examined the association between cytomegalovirus (CMV) infection and non-neutropenic fever immediately following autologous peripheral blood stem cell transplantation for a variety of haematological malignancies and solid tumours. Sixty non-neutropenic febrile episodes (41 in CMV-seropositive and 19 in CMV-seronegative patients) were evaluated. CMV reactivation, documented by CMV antigenaemia, was detected in 16 out of 41 (39%) seropositive patients compared with 0 out of 19 seronegative patients. In 12 of these 16 patients, CMV infection was considered the sole cause of fever. Thirteen patients had maximum antigenaemia levels > 5 cells/slide. Specific antiviral treatment led to the resolution of the fever in all, but two, patients, who developed fatal CMV pneumonia. Patients with multiple myeloma and lymphoma, possibly owing to a combination of disease-related characteristics and prior immunosuppressive treatment, had high rates of CMV reactivation and may require more frequent diagnostic evaluation and prompt therapeutic intervention.
引用
收藏
页码:237 / 241
页数:5
相关论文
共 11 条
[1]  
Alessandrino EP, 2000, BLOOD, V95, P4016
[2]   Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance [J].
Bilgrami, S ;
Aslanzadeh, J ;
Feingold, JM ;
Bona, RD ;
Clive, J ;
Dorsky, D ;
Edwards, RL ;
Tutschka, PJ .
BONE MARROW TRANSPLANTATION, 1999, 24 (01) :69-73
[3]  
BOECKH M, 1992, BLOOD, V80, P1358
[4]   Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation [J].
Boeckh, M ;
StevensAyers, T ;
Bowden, RA .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :907-912
[5]  
Boeckh M, 1995, Cancer Treat Res, V76, P97
[6]   GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].
GOODRICH, JM ;
BOWDEN, RA ;
FISHER, L ;
KELLER, C ;
SCHOCH, G ;
MEYERS, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178
[7]  
LJUNGMAN P, 1994, BONE MARROW TRANSPL, V13, P209
[8]   RISK-FACTORS FOR CYTOMEGALOVIRUS-INFECTION AFTER HUMAN MARROW TRANSPLANTATION [J].
MEYERS, JD ;
FLOURNOY, N ;
THOMAS, ED .
JOURNAL OF INFECTIOUS DISEASES, 1986, 153 (03) :478-488
[9]  
REUSSER P, 1990, BLOOD, V75, P1888
[10]   Cytomegaloviremia after autografting for leukemia: Clinical significance and lack of effect on engraftment [J].
Singhal, S ;
Powles, R ;
Treleaven, J ;
Horton, C ;
Pinkerton, CR ;
Meller, S ;
Mehta, J .
LEUKEMIA, 1997, 11 (06) :835-838